Resección tarsal vertical limitada en un caso de carcinoma basocelular de párpado inferior / Limited vertical tarsal resection in a case of basal cell carcinoma of the lower eyelid

Exponemos el caso clínico de una mujer de 71 años de edad con antecedente de múltiples carcinomas basocelulares (CBC) que presenta una lesión nodular en la totalidad de la extensión del borde libre de párpado inferior. Se realiza un abordaje de la lesión mediante exéresis del margen palpebral con resección limitada vertical de tarso y colgajo de Tripier con un resultado estético y funcional correcto, márgenes histológicos libres y ausencia de recidiva en un seguimiento de 12 meses (AU)

We present the clinical case of a 71-year-old woman with a history of multiple basal cell carcinomas (BCC) who presented a nodular lesion in practically the entire extension of the free edge of the lower eyelid. The lesion was approached by excision of the palpebral margin with limited vertical resection of the tarsus and Tripier flap with a correct aesthetic and functional result, free histological margins and no recurrence in a 12-month follow-up (AU)

Limited vertical tarsal resection in a case of basal cell carcinoma of the lower eyelid.

We present the clinical case of a 71-year-old woman with a history of multiple basal cell carcinomas (BCC) who presented a nodular lesion in practically the entire extension of the free edge of the lower eyelid. The lesion was approached by excision of the palpebral margin with limited vertical resection of the tarsus and Tripier flap with a correct aesthetic and functional result, free histological margins and no recurrence in a 12-month follow-up.

Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis.

A 60-year-old woman received a single 5-mg dose of zoledronic acid (Aclasta) for treatment of postmenopausal osteoporosis. One day after receiving the drug, she acutely developed a painful periorbital swelling, chemosis, and hyperemia in the right eye. The condition worsened despite initial treatment with topical steroids. An orbital CT scan showed right eye proptosis, eyelid edema, and intraorbital fat stranding. A diagnosis of orbital inflammatory disease was made, and the patient was treated with high-dose oral steroids (prednisone 80 mg/day) tapered along 6 weeks. The symptoms and the swelling reduced progressively after initiating oral prednisone, and after 12 days, there was complete resolution of the condition. The patient remained symptom free and had no remission after the treatment interruption.

The effect of increasing doses of levodopa on children with strabismic amblyopia.

PURPOSE: The purpose of this study was to determine the efficacy and tolerance of a levodopa/carbidopa combination and to test its dose-effect response when combined with occlusion therapy for children with amblyopia. METHODS: A 1-week randomized, double-blind, parallel, and placebo-controlled study was performed with 78 children with amblyopia aged between 7 and 17 years. Children who weighed less than 40 kg were randomly assigned to receive 5, 10, or 20 mg of levodopa or placebo (3 times a day), and those who weighed 40 kg or more were randomly assigned to receive 10, 20, or 40 mg of levodopa or placebo. Subjects were instructed to occlude the dominant eye (3 h/d). Snellen visual acuity was measured at baseline and at 2 hours after ingestion of the last capsule. Compliance with occlusion and capsule consumption was verified by a questionnaire and counting capsules. Adverse effects were checked with a physical examination and a questionnaire. RESULTS: From baseline to the follow-up test trial, the improvement in the logarithm of the Snellen fraction was 0.05+/-0.11 in the placebo group, 0.18 +/-0.21 in group 1, 0.08+/-0.11 in group II, and 0.16+/-0.15 in group III (P = .031). Visual acuity improved from 0.59 to 0.45 in the levodopa/carbidopa group and from 0.69 to 0.63 in the control group (P = .023). The compliance with occlusion was similar in all groups. No one complained of adverse side effects. CONCLUSION: Levodopa, at an average dose of 0.51 mg/kg per day, is well tolerated and produces a clinical and statistically significant short-term improvement of visual acuity in children with amblyopia.